A comparative study of 131I and 177Lu labeled somatostatin analogues for therapy of neuroendocrine tumours

Applied Radiation and Isotopes

Volumn 67, Issue 2, 2009, Pages 227-233

  de Araujo E B ^a   Caldeira Filho, J S ^a   Nagamati, L T ^a   Muramoto, E ^a   Colturato, M T ^a   Couto, R M ^a   Pujatti, P B ^a   Mengatti, J ^a   Silva, C P G ^a  

^a INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

Author keywords

131I; 177L; Neuroendocrine tumours; Radiolabeling; Somatostatin analogues; Target therapy

Indexed keywords

AMINES; LUTETIUM; ONCOLOGY;

131I; 177L; NEUROENDOCRINE TUMOURS; RADIOLABELING; SOMATOSTATIN ANALOGUES;

TUMORS;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE OCTREOTATE I 131; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE OCTREOTATE LU 177; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; CHELATING AGENT; DIAGNOSTIC AGENT; DRUG DERIVATIVE; LUTETIUM; RADIOACTIVE IODINE; RADIOISOTOPE; SINGLE HETEROCYCLIC RINGS; SOMATOSTATIN;

ABDOMEN; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER THERAPY; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG UPTAKE; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; RADIOIODINATION; RAT; ANIMAL; PHARMACOKINETICS; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; CHELATING AGENTS; HETEROCYCLIC COMPOUNDS, 1-RING; IODINE RADIOISOTOPES; LUTETIUM; MICE; NEUROENDOCRINE TUMORS; PHARMACOKINETICS; RADIOISOTOPES; RADIOPHARMACEUTICALS; SOMATOSTATIN; TISSUE DISTRIBUTION;

EID: 58149087504     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2008.09.009     Document Type: Article

References (23)

1. Bakker W.H., Kreening E.P., and Breeman W.A. Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals. J. Nucl. Med. 31 (1990) 1501-1509
2. Bakker W.H., Breeman W.A., De Jong M., Visser T.J., and Krenning E.P. Iodine-131 labeled octreotide: not an option for somatostatin receptor therapy. Eur. J. Nucl. Med. 23 (1996) 775-781
3. 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur. J. Nucl. Med. 30 (2003) 207-216
4. 3]octreotide. Eur. J. Nucl. Med. 20 (1993) 1089-1094
5. Breeman W.A.P., de Jong M., and Kwekkeboom D.J. Somatostatine receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur. J. Nucl. Med. 28 (2001) 1421-1429
6. 177Lu at high specific activities. Eur. J. Nucl. Med. Mol. Imaging 30 (2003) 917-920
7. 3]octreotide. Bioconjugated Chem. 10 (1999) 431-438
8. Forrer F., Uusijärvi H., Storch D., Maecke H.R., and Mueller-Brand J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumours after treatment with 90Y-DOTATOC. J. Nucl. Med. 46 8 (2005) 1310-1316
9. Froidevausx S., Heppeler A., Eberle A.N., Meier A.M., Häusler M., Beglinger C., Béhé M., Powell P., and Mäeke H.R. Preclinical comparison in AR4-2J tumour-bearing mice of four radiolabeled 1,4,7,10-tetraacetic acid-somatostatin analogs for tumour diagnosis and internal radiotherapy. Endocrinology 141 9 (2000) 3304-3312
10. Froidevausx S., Eberle A.N., Christe M., Sumanovski L., Heppeler A., Schmitt J.S., Eisenwiener K., Beglinger C., and Maeke H.R. Neuroendocrine tumour targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumour model. Int. J. Cancer 98 (2002) 930-937
11. Hofland L.J., Van Koetsveld P.M., Waaijers M., and Lamberts S.W.J. Internalisation of isotope-coupled somatostatin analogues. Digestion 57 Suppl. 1 (1996) 2-6
12. 90Y-labeled somatostatin analogues. J. Nucl. Med. 46 1 (2005) 13S-17S
13. 3-octreotide. J. Nucl. Med. 33 (1992) 652-658
14. 0]octreotide in patients. Eur. J. Nucl. Med. 28 (2001) 1319-1325
15. 177Lu-DOTA0,Try3]octreotate. Eur. J. Nucl. Med. 30 (2003) 417-422
16. Lamberts S.W., Koper J.W., and Reubi J.C. Potencial role of somatostatin analogues in the treatment of cancer. Eur. J. Clin. Invest. 17 (1987) 281-287
17. Oyen, W.J.G., Bodei, L., Giammarile, F., Maecke, H.R., Tenvall, J., Luster, M., Brans, B., 2007. Targeted therapy in nuclear medicine-current status and future prospects. Ann. Oncol. (April).
18. 177Lu for radionuclide therapy. Appl. Radiat. Isot. 59 (2003) 109-118
19. Reubi J.C., Schär J.C., Waser B., Wenger S., Heppeler A., Schmitt J.S., and Macke H.R. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 27 (2000) 273-282
20. Rufini V., Calcagni M.L., and Baurn R.P. Imaging of neuroendocrine tumours. Semin. Nucl. Med. 36 3 (2006) 228-247
21. 90Y-DOTATOC. J. Nucl. Med. 43 (2002) 610-616
22. Wester H.J., Schottelius M., Scheidhauer K., Reubi J.C., Wolf I., and Schwaiger M. Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics. Eur. J. Nucl. Med. 29 (2002) 28-338
23. Zalutsky M.R. Radionuclide Therapy. In: Vértes A., Nagy S., and Zoltán K. (Eds). Handbook of Nuclear Chemistry vol. 4 (2003), Kluwer Academic Publishers, Netherlands